Key result
Gliclazide modified release is associated with a low rate of hypoglycemia and proven cardiovascular safety in type 2 diabetes, while ACE inhibitors like perindopril are effective for managing hypertension in the Gulf region.
Why the study?
Given the particularly high prevalence of diabetes and hypertension in the Gulf region, better management has the potential to dramatically reduce adverse cardiovascular outcomes.
This symposium summary emphasizes the importance of tailored management of type 2 diabetes and hypertension in the Gulf region, supporting the use of late-generation sulfonylureas and combination antihypertensive therapies.
Supports individualized therapy in Gulf-region T2D; leaves open confirmation of CV benefits in dedicated trials.
Cardiovascular disease (CVD) is a leading cause of death globally, driven by the high rates of risk factors, such as diabetes and hypertension. As the prevalence of these risk factors is particularly high in the Gulf region, better diagnosis and management of type 2 diabetes (T2D) and hypertension has the potential to dramatically reduce adverse cardiovascular outcomes for individuals in that part of the world. This article provides a summary of presentations made during the EVIDENT summit, a virtual symposium on Evidence in Diabetes and Hypertension, held in September 2021, including a review of the various guidelines for both T2D and hypertension, as well as recent findings relevant to the safety and efficacy for therapies relating to these conditions. Of relevance to the Gulf region, the risk of hypoglycaemia with sulfonylureas during Ramadan was reviewed. For the management of T2D, sulfonylureas have been a long-standing medication used to achieve glycaemic control; however, differences have emerged between early and later generations, with recent studies suggesting improvements in the safety profiles of late-generation sulfonylureas. For patients with hypertension, incremental therapy changes are recommended to reduce the risk of cardiovascular complications that are associated with increasing blood pressure. For first-line therapy, angiotensin-converting enzyme inhibitors (ACEi), such as perindopril, have been demonstrated to reduce the risk of cardiovascular and all-cause mortality. The addition of calcium channel blockers and diuretics to ACEi has been shown to be effective in patients with poorly controlled hypertension. The different renin-angiotensin-aldosterone system inhibitors are reviewed, and the benefit of combination therapies, including amlodipine and indapamide in patients with difficult-to-control hypertension, is investigated. The benefits of lifestyle modifications for these patients are also discussed, with important clinical considerations that are expected to inform patient management in daily clinical practice.
No takes yet. Share an insight, caveat, or question.
Hassanein et al. (2022) conducted a review in Type 2 Diabetes and Hypertension. Gliclazide MR and Perindopril was evaluated. Gliclazide modified release is associated with a low rate of hypoglycemia and proven cardiovascular safety in type 2 diabetes, while ACE inhibitors like perindopril are effective for managing hypertension in the Gulf region.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: